Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

882 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial.
Pennesi E, Michels N, Brivio E, van der Velden VHJ, Jiang Y, Thano A, Ammerlaan AJC, Boer JM, Beverloo HB, Sleight B, Chen Y, Vormoor-Bürger B, Rives S, Bielorai B, Rössig C, Petit A, Rizzari C, Engstler G, Starý J, Bautista Sirvent FJ, Chen-Santel C, Bruno B, Bertrand Y, Rialland F, Plat G, Reinhardt D, Vinti L, Von Stackelberg A, Locatelli F, Zwaan CM. Pennesi E, et al. Among authors: reinhardt d. Leukemia. 2022 Jun;36(6):1516-1524. doi: 10.1038/s41375-022-01576-3. Epub 2022 Apr 25. Leukemia. 2022. PMID: 35468945 Free PMC article. Clinical Trial.
Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study.
Zwaan CM, Reinhardt D, Zimmerman M, Hasle H, Stary J, Stark B, Dworzak M, Creutzig U, Kaspers GJ; International BFM Study Group on Paediatric AML. Zwaan CM, et al. Among authors: reinhardt d. Br J Haematol. 2010 Mar;148(5):768-76. doi: 10.1111/j.1365-2141.2009.08011.x. Epub 2009 Dec 8. Br J Haematol. 2010. PMID: 19995399 Free article. Clinical Trial.
Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM, Rizzari C, Mechinaud F, Lancaster DL, Lehrnbecher T, van der Velden VH, Beverloo BB, den Boer ML, Pieters R, Reinhardt D, Dworzak M, Rosenberg J, Manos G, Agrawal S, Strauss L, Baruchel A, Kearns PR. Zwaan CM, et al. Among authors: reinhardt d. J Clin Oncol. 2013 Jul 1;31(19):2460-8. doi: 10.1200/JCO.2012.46.8280. Epub 2013 May 28. J Clin Oncol. 2013. PMID: 23715577 Clinical Trial.
An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia.
Kaspers GJL, Niewerth D, Wilhelm BAJ, Scholte-van Houtem P, Lopez-Yurda M, Berkhof J, Cloos J, de Haas V, Mathôt RA, Attarbaschi A, Baruchel A, de Bont ES, Fagioli F, Rössig C, Klingebiel T, De Moerloose B, Nelken B, Palumbo G, Reinhardt D, Rohrlich PS, Simon P, von Stackelberg A, Zwaan CM. Kaspers GJL, et al. Among authors: reinhardt d. Br J Haematol. 2018 May;181(4):523-527. doi: 10.1111/bjh.15233. Epub 2018 Apr 20. Br J Haematol. 2018. PMID: 29676440 Free article. Clinical Trial.
Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.
van Eijkelenburg NKA, Rasche M, Ghazaly E, Dworzak MN, Klingebiel T, Rossig C, Leverger G, Stary J, De Bont ESJM, Chitu DA, Bertrand Y, Brethon B, Strahm B, van der Sluis IM, Kaspers GJL, Reinhardt D, Zwaan CM. van Eijkelenburg NKA, et al. Among authors: reinhardt d. Haematologica. 2018 Sep;103(9):1484-1492. doi: 10.3324/haematol.2017.187153. Epub 2018 May 17. Haematologica. 2018. PMID: 29773602 Free PMC article. Clinical Trial.
Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group.
Niktoreh N, Lerius B, Zimmermann M, Gruhn B, Escherich G, Bourquin JP, Dworzak M, Sramkova L, Rossig C, Creutzig U, Reinhardt D, Rasche M. Niktoreh N, et al. Among authors: reinhardt d. Haematologica. 2019 Jan;104(1):120-127. doi: 10.3324/haematol.2018.191841. Epub 2018 Aug 9. Haematologica. 2019. PMID: 30093401 Free PMC article. Clinical Trial.
Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis.
Zwaan CM, Reinhardt D, Corbacioglu S, van Wering ER, Bökkerink JP, Tissing WJ, Samuelsson U, Feingold J, Creutzig U, Kaspers GJ. Zwaan CM, et al. Among authors: reinhardt d. Blood. 2003 May 15;101(10):3868-71. doi: 10.1182/blood-2002-07-1947. Epub 2003 Jan 23. Blood. 2003. PMID: 12543868 Free article. Clinical Trial.
Acute leukemias in children with Down syndrome.
Zwaan CM, Reinhardt D, Hitzler J, Vyas P. Zwaan CM, et al. Among authors: reinhardt d. Hematol Oncol Clin North Am. 2010 Feb;24(1):19-34. doi: 10.1016/j.hoc.2009.11.009. Hematol Oncol Clin North Am. 2010. PMID: 20113894 Review.
Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia.
Balgobind BV, Hollink IH, Arentsen-Peters ST, Zimmermann M, Harbott J, Beverloo HB, von Bergh AR, Cloos J, Kaspers GJ, de Haas V, Zemanova Z, Stary J, Cayuela JM, Baruchel A, Creutzig U, Reinhardt D, Pieters R, Zwaan CM, van den Heuvel-Eibrink MM. Balgobind BV, et al. Among authors: reinhardt d. Haematologica. 2011 Oct;96(10):1478-87. doi: 10.3324/haematol.2010.038976. Epub 2011 Jul 26. Haematologica. 2011. PMID: 21791472 Free PMC article.
882 results